Several telehealth companies now sell “microdose” GLP-1 programs as a distinct product, usually at a lower price. We flagged this in three of our provider reviews before looking properly at the evidence. Having looked, the picture is consistent — and there is one important distinction most coverage misses.
What microdosing means
GLP-1 medications are approved with a titration schedule: you start low to limit gastrointestinal side effects, then escalate over weeks toward a maintenance dose. The weight-loss results reported in trials like STEP 1 and SURMOUNT-1 come from people who reached those maintenance doses.
Microdosing means deliberately staying below that schedule — typically at or under a starting dose, indefinitely. It is sometimes pitched as a gentler route, sometimes as a maintenance strategy, and often simply as a cheaper one.
The regulatory position is unambiguous
Clinical sources are unusually consistent here, and none of them hedge.
- Hackensack Meridian Health quotes a physician stating that “the effects of microdosing GLP-1s have not been clinically tested, and these doses are not FDA approved.”
- An NIH-hosted review describes microdosing semaglutide as off-label and not endorsed by the manufacturer, noting that no clinical trials have validated its safety or efficacy.
- UW Medicine states it has not been studied or FDA-approved, so whether it is safe or effective is unknown.
- US News notes that because it has not been clinically tested or FDA-approved, it carries unpredictable short- and long-term effects.
- One published assessment observes that the majority of supporting evidence is anecdotal reports and observations rather than robust research.
Cleveland Clinic goes further on outcomes, stating that microdosing is not as effective as standard dosing — which is what you would expect. Across every GLP-1 with published dose-ranging data, the response is clearly dose-dependent. Orforglipron produced 7.4% average weight loss at 5.5 mg and 11.1% at 17.2 mg over the same 72 weeks. Less drug, less effect.
The distinction that actually matters
A monitored low dose is not the same thing as a microdose program
Cedars-Sinai notes that lower doses of FDA-approved GLP-1 medications may be used safely when prescribed and monitored by a clinician. If your doctor holds you at 0.5 mg because you are losing weight steadily and tolerating it, or because escalating made you ill, that is ordinary clinical judgement applied to your situation. It is not the same as buying a product marketed as “microdosing” at a lower price point.
This is the nuance that both cheerleading and alarmist coverage tend to lose. The criticism is not “low doses are dangerous.” It is that a marketed program built around sub-therapeutic dosing, sold without a published clinical rationale, is a commercial proposition wearing clinical clothing.
The risks
Two are worth understanding specifically.
Dosing error. Cleveland Clinic notes microdosing raises the risk of dosing errors and of side effects such as nausea or diarrhea. Approved products are built around fixed doses — a pen click, a pre-filled vial. Drawing a non-standard fraction introduces measurement error in both directions, and the direction that overshoots is the one that makes you sick.
Compounded formulations compound the problem. Microdosing is most often offered using compounded preparations, and one clinical source flags the additional risks that brings: uncertain drug quality and imprecise dosing. You are stacking an unvalidated dosing strategy on top of a product the FDA has not evaluated. Our brand-name versus compounded guide covers that second layer.
Who is selling it
Among the providers we have reviewed, three offer microdosing products: Noom markets a Microdose GLP-1Rx program at a $49 introductory price, Fridays sells compounded microdose semaglutide and tirzepatide, and Lemonaid Health lists a compounded tirzepatide microdosing option.
None of the three publishes a clinical rationale or evidence base for the approach on the pages we reviewed. We are not suggesting any of them is doing anything unlawful, and a clinician reviews each case. But a company selling a dosing strategy that no trial has validated should be able to explain, in writing, why it works and for whom.
One combination we would question harder
Fridays publishes a minimum BMI of 20 — inside the normal weight range and far below the BMI 30, or 27 with a comorbidity, that weight-management GLP-1s are approved for — alongside its microdose products. A permissive eligibility floor and a sub-therapeutic dosing product point in the same direction, and that direction is worth thinking about before enrolling.
Questions to ask
If a provider offers you a microdose program, or if you are considering asking your own clinician about a lower dose, these five questions separate a clinical decision from a product:
- What is the goal of the lower dose for me specifically? Tolerance? Maintenance after weight loss? Cost? Each implies a different plan.
- What evidence supports it? “Many patients do well” is an observation, not evidence.
- How will the dose be measured accurately? This is where errors happen.
- Is the product compounded? If so, you are accepting two layers of uncertainty rather than one.
- What happens if it does not work? Is there a path to standard dosing, and what does that cost?
The bottom line
Microdosing has not been clinically tested, is not FDA-approved dosing, and is described by clinical sources as off-label and unvalidated. The dose-dependent response seen across this drug class makes it unsurprising that Cleveland Clinic describes it as less effective than standard dosing.
None of that makes a lower dose wrong for you. A clinician who knows your history and monitors your response may have a perfectly good reason to keep you there, and Cedars-Sinai is clear that lower doses of approved medications can be used safely under that supervision. The thing to be sceptical of is not the dose. It is a program sold around the dose, at a lower price, without an explanation attached.
Frequently Asked Questions
What is GLP-1 microdosing?+
Using doses below the titration schedule established in clinical trials and reflected in the FDA-approved labelling. In practice it usually means staying at or below a starting dose long-term, rather than escalating toward the doses the trials tested for weight loss.
Is microdosing FDA-approved?+
No. Multiple clinical sources state the same thing: microdosing has not been clinically tested and these doses are not FDA-approved. An NIH-hosted review describes microdosing semaglutide as off-label and not endorsed by the manufacturer, noting that no clinical trials have validated its safety or efficacy.
Is there any evidence it works?+
Very little of the kind that would settle the question. One published assessment notes that the majority of evidence supporting GLP-1 microdosing is based on anecdotal reports and observations rather than robust research. Cleveland Clinic states it is not as effective as standard dosing — which is the expected result given the dose-dependent response seen across this drug class.
So is a lower dose always wrong?+
No, and this is the distinction that matters. Cedars-Sinai notes that lower doses of FDA-approved GLP-1 medications may be used safely when prescribed and monitored by a clinician. A doctor holding you at a lower dose because you are responding well or tolerating it poorly is ordinary clinical judgement. That is different from buying a marketed "microdose program" as a product.
What are the risks?+
Cleveland Clinic notes microdosing raises the risk of dosing errors and of side effects such as nausea or diarrhea — largely because drawing a non-standard dose invites measurement error. Where microdosing uses compounded formulations, one clinical source flags additional risks including uncertain drug quality and imprecise dosing. US News and UW Medicine both note that because it has not been studied, short- and long-term effects are unpredictable.
Why do telehealth companies sell it?+
A smaller dose costs less to supply, which supports a lower advertised price and widens the addressable market to people who would not qualify for or want standard dosing. We are not in a position to attribute motive to any specific company — but the commercial logic is straightforward, and it is a reason to ask for the clinical rationale rather than assume one exists.
What should I ask if a provider offers it?+
Ask what clinical goal the lower dose is meant to achieve for you specifically, what evidence supports it, how the dose will be measured accurately, whether the product is compounded, and what the plan is if it does not work. A clinician with a real rationale will answer all five. A program built around a price point may not.
Sources
- Hackensack Meridian Health — “Is Microdosing GLP-1s Safe?” (not clinically tested; doses not FDA approved)
- Cleveland Clinic Health Essentials — “Can You Microdose Ozempic and Other GLP-1s?” (dosing error risk, side effects, less effective than standard dosing)
- Cedars-Sinai — lower doses of FDA-approved GLP-1 medications may be used safely when prescribed and monitored by a clinician
- NIH / PMC — “Understanding Microdosing Semaglutide” (off-label, not manufacturer-endorsed, no trials validating safety or efficacy)
- UW Medicine, Right as Rain — not studied or FDA-approved; safety and efficacy unknown
- US News Health — unpredictable short- and long-term effects absent clinical testing
- Published commentary noting the evidence base is largely anecdotal; and that compounded formulations used for microdosing carry uncertain drug quality and imprecise dosing
- Dose-response figures from Lilly's published orforglipron trial data, cited in our orforglipron guide. Verified August 5, 2026.
🇺🇸Medical Disclaimer
Your health, your doctor. This article summarises published clinical commentary on an off-label dosing practice. It is not medical advice, and we are researchers rather than clinicians. Never change your dose — up or down — without the clinician managing your care. If you are currently on a microdose program and it is working for you, this article is not a reason to stop; it is a reason to ask your prescriber what the plan is.